Combinational drug-loaded lipid nanocapsules for the treatment of cancer.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
05 Oct 2019
Historique:
received: 26 06 2019
revised: 30 07 2019
accepted: 31 07 2019
pubmed: 5 8 2019
medline: 31 1 2020
entrez: 5 8 2019
Statut: ppublish

Résumé

The purpose of this study was to investigate the feasibility of an intravenously administered combinational therapy using lipid nanocapsules (LNCs) as a drug delivery carrier for the treatment of different cancers. Therefore, we encapsulated 6 anticancer drugs within LNCs. Their size was approximately 50 nm. Except for oxaliplatin, their encapsulation efficiency, which was measured by different analytical methods, varied between 75% for SN38 to 100% for regorafenib. The in vitro studies showed a nonsignificant difference between the cytotoxicity of free and encapsulated drugs and a significant decrease in haemolysis by encapsulation in LNCs. Finally, the in vivo experiment showed that a combinational regimen of SN38-LNCs and regorafenib-LNCs abates CT26 murine colorectal cancer growth and increases median survival time.

Identifiants

pubmed: 31377406
pii: S0378-5173(19)30633-7
doi: 10.1016/j.ijpharm.2019.118588
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Drug Combinations 0
Lipids 0
Nanocapsules 0
Phenylurea Compounds 0
Pyridines 0
regorafenib 24T2A1DOYB
Irinotecan 7673326042

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118588

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Nikolaos Tsakiris (N)

Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium.

Malamatenia Papavasileiou (M)

Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium.

Elia Bozzato (E)

Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium.

Alessandra Lopes (A)

Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium.

Arnaud M Vigneron (AM)

Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France.

Véronique Préat (V)

Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium. Electronic address: veronique.preat@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH